Alaunos Therapeutics prices $15.7M public offering of 24.2M shares at $0.62/share

Alaunos Therapeutics, Inc.

Priced 24,228,719 shares at $0.6191 per share for gross proceeds of $15.7M.
Net proceeds expected ~$14.6M after underwriting discounts and estimated expenses.
Underwriter granted 30-day option to purchase up to 3,634,307 additional shares.
Proceeds to fund continued development of product candidates and for working capital.
Offering expected to close on or about December 1, 2022.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Alaunos Therapeutics, Inc. entered into Underwriting Agreement with Cantor Fitzgerald & Co. valued at approximately $14.6 million (effective 2022-11-29).

Action: entry
Agreement: underwriting
Counterparty: Cantor Fitzgerald & Co.
Value: approximately $14.6 million
Effective: 2022-11-29

Exact text from the filing

On November 29, 2022, Alaunos Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. (the “Underwriter”), as the sole underwriter, relating to the issuance and sale in an underwritten offering (the “Offering”) of 24,228,719 shares (the “Firm Shares”) of the Company’s common stock, par value $0.001 per share, to the Underwriter at a price of $0.6191 per share.

View on SEC.gov

Browse all material agreements →

Alaunos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-295491

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.